U.S. markets closed

Aspen Pharmacare Holdings Limited (APNHY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
9.580.00 (0.00%)
At close: 09:48AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close9.58
Bid0.00 x 0
Ask0.00 x 0
Day's Range9.58 - 9.58
52 Week Range7.77 - 18.79
Avg. Volume703
Market Cap4.36B
Beta (5Y Monthly)0.70
PE Ratio (TTM)11.97
EPS (TTM)0.80
Earnings DateN/A
Forward Dividend & Yield0.17 (1.81%)
Ex-Dividend DateSep 22, 2021
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for APNHY

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    Analyst Report: MERCK Kommanditgesellschaft auf AktienMerck KGaA operates in three main segments: life sciences, performance materials, and healthcare. The life sciences segment (46% of 2021 sales) provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. In the healthcare segment (36%), Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In its electronics segment (18%), the company offers specialty materials to manufacture a variety of products, such as semiconductors, flat-screen televisions, automobiles, and cosmetics. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
    Fair Value
    Economic Moat
    11 days agoMorningstar
View more
  • Reuters

    UPDATE 1-Africa CDC hopeful Aspen will get COVID vaccine orders

    Africa's top public health body said on Thursday it was hopeful South African pharmaceutical firm Aspen Pharmacare would get orders for its own brand COVID-19 vaccine. Africa Centers for Disease Control and Prevention (CDC) said last month that it is in detailed discussions with buyers to generate demand for Aspen's COVID-19 vaccine Aspenovax. Just one fifth of adults in Africa are fully vaccinated against COVID-19, but demand has fallen across the continent which already receives donated vaccines from Western countries and has supplies to hand from earlier purchases.

  • Reuters

    UPDATE 1-Aspen COVID vaccine lines risk going idle as J&J orders dwindle

    South Africa's Aspen Pharmacare's COVID-19 vaccine production lines may soon go idle, and without any new orders it could be forced to pivot to manufacturing other products, a senior executive said on Wednesday. Aspen currently produces vaccines for Johnson & Johnson and, in March, it struck a deal to produce, price, and sell its own-brand version of the shot for African markets. Aspen has had no orders for its Aspenovax vaccine, and it is not possible to predict future J&J demand, Stavros Nicolaou, Aspen Group Senior Executive, told Reuters, leaving the future of its 450-million-dose annual production capacity in doubt.

  • Reuters

    S.Africa's Aspen to halt COVID vaccine output as J&J orders dry up

    South Africa's Aspen Pharmacare will stop making COVID-19 vaccines from the end of this month due to a lack of orders, a senior executive said, further undermining Africa's already meager capacity to produce doses. Aspen currently produces vaccines for Johnson & Johnson .